Eikon Therapeutics, Inc. EIKN
- EIK1001 — Melanoma Phase 2
- EIK1001 — Non-Small Cell Lung Cancer Phase 2
TLR8 (2 companies · 3 programs)
Companies with an active program directed at TLR8.
ImmunityBio, Inc. IBRX
- 3M-052
Companies with an active program directed at TLR8.